255 related articles for article (PubMed ID: 27258253)
41. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
42. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
43. Chemoradiotherapy for stage III non-small cell lung cancer: have we reached the limit?
Xu P; Le Pechoux C
Chin Clin Oncol; 2015 Dec; 4(4):45. PubMed ID: 26730757
[TBL] [Abstract][Full Text] [Related]
44. Radical treatment of non-small cell lung cancer during the last 5 years.
McCloskey P; Balduyck B; Van Schil PE; Faivre-Finn C; O'Brien M
Eur J Cancer; 2013 May; 49(7):1555-64. PubMed ID: 23352436
[TBL] [Abstract][Full Text] [Related]
45. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
Schena M; Guarrera S; Buffoni L; Salvadori A; Voglino F; Allione A; Pecorari G; Ruffini E; Garzino-Demo P; Bustreo S; Consito L; Bironzo P; Matullo G
DNA Repair (Amst); 2012 Apr; 11(4):374-80. PubMed ID: 22284908
[TBL] [Abstract][Full Text] [Related]
46. [Multimodal Treatment of Non-Small Cell Lung Cancer with Cerebral Metastases].
Kudelin N; Bölükbas S; Schirren J
Zentralbl Chir; 2015 Jun; 140(3):328-33. PubMed ID: 26114639
[TBL] [Abstract][Full Text] [Related]
47. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Balducci L; Ciardiello F; Di Maio M; Felip E; Langer C; Lilenbaum RC; Perrone F; Senan S; de Marinis F
Clin Lung Cancer; 2015 Sep; 16(5):325-33. PubMed ID: 25862554
[TBL] [Abstract][Full Text] [Related]
48. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.
Ling C; Xie Y; Zhao D; Zhu Y; Xiang J; Yang J
Cancer Gene Ther; 2012 Oct; 19(10):697-706. PubMed ID: 22863759
[TBL] [Abstract][Full Text] [Related]
49. Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.
Di Paolo A; Del Re M; Petrini I; Altavilla G; Danesi R
Epigenomics; 2016 Aug; 8(8):1151-67. PubMed ID: 27479016
[TBL] [Abstract][Full Text] [Related]
50. [What is the value of neoadjuvant therapy in bronchial carcinoma?].
Digel W; Brethner L; Hasse J
Zentralbl Chir; 2000; 125(4):315-8. PubMed ID: 10829310
[TBL] [Abstract][Full Text] [Related]
51. MicroRNAs, DNA Damage Response, and Cancer Treatment.
He M; Zhou W; Li C; Guo M
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973455
[TBL] [Abstract][Full Text] [Related]
52. Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC).
Zadeh FA; Raji A; Ali SA; Abdelbasset WK; Alekhina N; Iswanto AH; Terefe EM; Jalil AT
Pathol Res Pract; 2022 May; 233():153823. PubMed ID: 35398616
[TBL] [Abstract][Full Text] [Related]
53. Epigenetics in non-small cell lung carcinomas.
Peralta-Arrieta I; Armas-López L; Zúñiga J; Ávila-Moreno F
Salud Publica Mex; 2019; 61(3):318-328. PubMed ID: 31276346
[TBL] [Abstract][Full Text] [Related]
54. The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer.
Harrow S; Hanna GG; Faivre-Finn C; McDonald F; Chalmers AJ
Clin Oncol (R Coll Radiol); 2016 Nov; 28(11):720-725. PubMed ID: 27591000
[TBL] [Abstract][Full Text] [Related]
55. The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?
Sadoughi F; Mirsafaei L; Dana PM; Hallajzadeh J; Asemi Z; Mansournia MA; Montazer M; Hosseinpour M; Yousefi B
DNA Repair (Amst); 2021 May; 101():103074. PubMed ID: 33640757
[TBL] [Abstract][Full Text] [Related]
56. A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives.
Sulewska A; Pilz L; Manegold C; Ramlau R; Charkiewicz R; Niklinski J
Cells; 2023 Mar; 12(6):. PubMed ID: 36980246
[TBL] [Abstract][Full Text] [Related]
57. The roles of glucose metabolic reprogramming in chemo- and radio-resistance.
Lin J; Xia L; Liang J; Han Y; Wang H; Oyang L; Tan S; Tian Y; Rao S; Chen X; Tang Y; Su M; Luo X; Wang Y; Wang H; Zhou Y; Liao Q
J Exp Clin Cancer Res; 2019 May; 38(1):218. PubMed ID: 31122265
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer.
Yang S; Huang Y; Zhao Q
Front Immunol; 2022; 13():878740. PubMed ID: 35514980
[TBL] [Abstract][Full Text] [Related]
59. The Long Run towards Personalized Therapy in Non-Small-Cell Lung Cancer: Current State and Future Directions.
Genova C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175919
[TBL] [Abstract][Full Text] [Related]
60. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.
Burgess JT; Rose M; Boucher D; Plowman J; Molloy C; Fisher M; O'Leary C; Richard DJ; O'Byrne KJ; Bolderson E
Front Oncol; 2020; 10():1256. PubMed ID: 32850380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
